581 related articles for article (PubMed ID: 31806700)
1. Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.
Verbrugge FH; Martin AC; Siegal D; Pieper K; Illingworth L; Camm AJ; Fox KAA
Heart; 2020 Jun; 106(11):845-851. PubMed ID: 31806700
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
4. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
[TBL] [Abstract][Full Text] [Related]
5. [Anticoagulation in high thromboembolic risk after catheter ablation for atrial fibrillation: results from the German Ablation Registry].
Moser J; Kuck KH; Andresen D; Spitzer SG; Hoffmann E; Schumacher B; Eckardt L; Brachmann J; Lewalter T; Hochadel M; Senges J; Willems S; Hoffmann BA
Dtsch Med Wochenschr; 2014 Sep; 139(39):1923-8. PubMed ID: 25225860
[TBL] [Abstract][Full Text] [Related]
6. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.
Verheugt FWA; Ambrosio G; Atar D; Bassand JP; Camm AJ; Costabel JP; Fitzmaurice DA; Illingworth L; Goldhaber SZ; Goto S; Haas S; Jansky P; Kayani G; Stepinska J; Turpie AGG; van Eickels M; Kakkar AK;
Am J Med; 2019 Dec; 132(12):1431-1440.e7. PubMed ID: 31306621
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR
Thompson LE; Maddox TM; Lei L; Grunwald GK; Bradley SM; Peterson PN; Masoudi FA; Turchin A; Song Y; Doros G; Davis MB; Daugherty SL
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724655
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (
Patti G; Lucerna M; Pecen L; Siller-Matula JM; Cavallari I; Kirchhof P; De Caterina R
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28736385
[TBL] [Abstract][Full Text] [Related]
10. Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk.
Mascarenhas DAN; Sharma M; Ziegler PD; Kantharia BK
Acta Cardiol; 2019 Apr; 74(2):131-139. PubMed ID: 29863432
[TBL] [Abstract][Full Text] [Related]
11. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: A population-based study.
Lau WCY; Douglas IJ; Wong ICK; Smeeth L; Lip GYH; Leung WK; Siu CW; Cheung BMY; Mok MTC; Chan EW
Heart Rhythm; 2020 Jan; 17(1):33-40. PubMed ID: 31377423
[TBL] [Abstract][Full Text] [Related]
13. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
[TBL] [Abstract][Full Text] [Related]
14. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of CAS risk model and CHA
Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
[No Abstract] [Full Text] [Related]
16. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
[TBL] [Abstract][Full Text] [Related]
17. CHA
D'Souza M; Carlson N; Fosbøl E; Lamberts M; Smedegaard L; Nielsen D; Torp-Pedersen C; Gislason G; Schou M
Eur J Prev Cardiol; 2018 Apr; 25(6):651-658. PubMed ID: 29482441
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic Risk of Cessation of Oral Anticoagulation Post Catheter Ablation in Patients With and Without Atrial Fibrillation Recurrence.
Rong B; Han W; Lin M; Hao L; Zhang K; Chen T; Sha R; Wang J; Wang R; Zhong J
Am J Cardiol; 2020 Dec; 137():55-62. PubMed ID: 33002462
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
Volterrani M; Iellamo F; Rosano G; Guarini P; Pusineri E; Bonassi S; Chimini C; Zaccà F; Proto C;
Int J Cardiol; 2013 Oct; 168(5):4729-33. PubMed ID: 23948115
[TBL] [Abstract][Full Text] [Related]
20. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
